• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对替莫唑胺治疗有反应的侵袭性催乳素瘤：两例报告。

Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases.

作者信息

Davoudi Zahra, Hallajnejad Mohammad, Jamali Elena, Honarvar Mohammadjavad

机构信息

Department of Endocrinology Skull Base Research Center of Shahid Beheshti University of Medical Sciences Tehran Iran.

Department of Neurosurgery Skull Base Research Center of Shahid Beheshti University of Medical Sciences Tehran Iran.

出版信息

Clin Case Rep. 2022 Jul 18;10(7):e6087. doi: 10.1002/ccr3.6087. eCollection 2022 Jul.

DOI:10.1002/ccr3.6087
PMID:35865778
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9291256/
Abstract

Refractory aggressive prolactinomas are detected after the unresponsiveness to conventional therapies. We report two cases that underwent temozolomide treatment and have been in near-complete remission ever since. We suggest the pathology techniques for earlier detection and, subsequently, treatment with temozolomide to reduce morbidities and better respond to therapy.

摘要

难治性侵袭性催乳素瘤是在对传统治疗无反应后被发现的。我们报告了两例接受替莫唑胺治疗且此后一直处于近乎完全缓解状态的病例。我们建议采用病理技术进行早期检测，随后使用替莫唑胺进行治疗，以降低发病率并更好地应对治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b670/9291256/610dc88ed7e0/CCR3-10-e6087-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b670/9291256/121aa2be65c9/CCR3-10-e6087-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b670/9291256/437b2a85f66c/CCR3-10-e6087-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b670/9291256/b62ca5ecff82/CCR3-10-e6087-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b670/9291256/610dc88ed7e0/CCR3-10-e6087-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b670/9291256/121aa2be65c9/CCR3-10-e6087-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b670/9291256/437b2a85f66c/CCR3-10-e6087-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b670/9291256/b62ca5ecff82/CCR3-10-e6087-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b670/9291256/610dc88ed7e0/CCR3-10-e6087-g001.jpg

相似文献

1
Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases.对替莫唑胺治疗有反应的侵袭性催乳素瘤：两例报告。
Clin Case Rep. 2022 Jul 18;10(7):e6087. doi: 10.1002/ccr3.6087. eCollection 2022 Jul.
2
Temozolomide in the management of dopamine agonist-resistant prolactinomas.替莫唑胺治疗多巴胺激动剂抵抗性泌乳素瘤。
Clin Endocrinol (Oxf). 2012 Jun;76(6):877-86. doi: 10.1111/j.1365-2265.2012.04373.x.
3
Aggressive prolactinomas: how to manage?侵袭性泌乳素瘤：如何治疗？
Pituitary. 2020 Feb;23(1):70-77. doi: 10.1007/s11102-019-01000-7.
4
β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.β-连环蛋白在人类泌乳素细胞瘤细胞的膜中减少，并且它在泌乳素分泌肿瘤模型中被替莫唑胺抑制。
Tumour Biol. 2022;44(1):85-105. doi: 10.3233/TUB-211500.
5
Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes.侵袭性泌乳素瘤和癌中替莫唑胺无反应性：管理与结局
J Endocr Soc. 2021 Dec 22;6(2):bvab190. doi: 10.1210/jendso/bvab190. eCollection 2022 Feb 1.
6
Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay.采用体外 3D 球体培养实验评估替莫唑胺联合卡培他滨（CAPTEM）治疗难治性泌乳素瘤的疗效。
Pituitary. 2022 Apr;25(2):238-245. doi: 10.1007/s11102-021-01192-x. Epub 2021 Nov 13.
7
Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.难治性侵袭性垂体大泌乳素瘤的替莫唑胺化疗的早期识别与启动及长期持续缓解
World Neurosurg. 2018 Oct;118:118-124. doi: 10.1016/j.wneu.2018.07.082. Epub 2018 Jul 18.
8
Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists.病例报告：替莫唑胺治疗对多巴胺激动剂耐药的难治性泌乳素瘤。
Front Endocrinol (Lausanne). 2021 Mar 12;12:616339. doi: 10.3389/fendo.2021.616339. eCollection 2021.
9
Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.替莫唑胺治疗侵袭性泌乳素瘤：一例病例报告及最新文献综述
Medicine (Baltimore). 2017 Nov;96(47):e8733. doi: 10.1097/MD.0000000000008733.
10
The treatment of aggressive prolactinomas with everolimus.依维莫司治疗侵袭性泌乳素瘤。
Pituitary. 2023 Aug;26(4):474-481. doi: 10.1007/s11102-023-01340-5. Epub 2023 Jul 10.

引用本文的文献

1
Current and Perspective Approaches to the Treatment of Prolactinomas.泌乳素瘤治疗的当前及未来方法
Acta Med Litu. 2023;30(2):96-107. doi: 10.15388/Amed.2023.30.2.1. Epub 2023 Jul 31.

本文引用的文献

1
Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics.催乳素垂体腺瘤中 ERα66 及其新型变异异构体 ERα36 的表达模式及其与临床病理特征的关联。
Pituitary. 2020 Jun;23(3):232-245. doi: 10.1007/s11102-020-01029-z.
2
Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications.卡麦角林治疗垂体和其他肿瘤：新机制和潜在更广泛的应用。
Neuroendocrinology. 2020;110(6):477-488. doi: 10.1159/000504000. Epub 2019 Oct 10.
3
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy.
替莫唑胺及其他烷化剂在胶质母细胞瘤治疗中的应用
Biomedicines. 2019 Sep 9;7(3):69. doi: 10.3390/biomedicines7030069.
4
How and when to use temozolomide to treat aggressive pituitary tumours.何时以及如何使用替莫唑胺治疗侵袭性垂体肿瘤。
Endocr Relat Cancer. 2019 Aug;26(9):R545-R552. doi: 10.1530/ERC-19-0083.
5
Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.替莫唑胺细胞减灭治疗在巨大的卡麦角林抵抗的泌乳素分泌性垂体神经内分泌肿瘤中的应用。
Anticancer Drugs. 2019 Jun;30(5):533-536. doi: 10.1097/CAD.0000000000000768.
6
Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.难治性侵袭性垂体大泌乳素瘤的替莫唑胺化疗的早期识别与启动及长期持续缓解
World Neurosurg. 2018 Oct;118:118-124. doi: 10.1016/j.wneu.2018.07.082. Epub 2018 Jul 18.
7
Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.替莫唑胺治疗侵袭性泌乳素瘤：一例病例报告及最新文献综述
Medicine (Baltimore). 2017 Nov;96(47):e8733. doi: 10.1097/MD.0000000000008733.
8
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.侵袭性垂体肿瘤和癌的治疗：2016年欧洲内分泌学会（ESE）调查结果
Eur J Endocrinol. 2018 Mar;178(3):265-276. doi: 10.1530/EJE-17-0933. Epub 2018 Jan 12.
9
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.欧洲内分泌学会侵袭性垂体肿瘤和癌管理临床实践指南
Eur J Endocrinol. 2018 Jan;178(1):G1-G24. doi: 10.1530/EJE-17-0796. Epub 2017 Oct 18.
10
Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.替莫唑胺治疗耐药性泌乳素分泌型垂体腺瘤和癌：一项系统评价
Hormones (Athens). 2017 Apr;16(2):139-149. doi: 10.14310/horm.2002.1729.